Greater Cannabis (PK) (USOTC:GCAN)
Historical Stock Chart
From Jul 2019 to Jul 2024
GammaCan International, Inc. (OTC BB: GCAN), a developer of
immunotherapies for the treatment of melanoma and other cancers, today
announced the reorganization of its Board of Directors.
Mr. Steven Katz and Mr. Albert Passner have joined the Board of
Directors of GammaCan International Inc. Mr. Katz has also been named
Chairman of the Board. At the same time, Dr. Lior Soussan-Gutman and Mr.
Jean-Pierre Elisha Martinez have left the Board of GammaCan
International Inc. and continue as Directors of GammaCan Ltd., a
subsidiary.
“We are pleased to have Steven and Albert join
our Board. Steven brings extensive industry experience to GammaCan. He
is a successful entrepreneur, management consultant and life sciences
executive. GammaCan will be able to utilize Steven’s
industry background and experience as well as take advantage of both
Steven’s and Al’s
experience as Directors of public companies”,
commented Patrick Schnegelsberg, GammaCan’s
CEO.
Mr. Katz is currently the President of Steven Katz & Associates, Inc., a
health care and technology based management consulting firm specializing
in strategic planning, corporate development, new product planning,
technology licensing and structuring and securing various forms of
financing. Mr. Katz also served as President, Chief Operating Officer
and Director of Senesco Technologies, Inc., an American Stock Exchange
listed company, engaged in the identification and development of
proprietary gene technology with application to human, animal and plant
systems. He co-founded and served as Executive Vice President of S.K.Y.
Polymers, Inc., a bio-materials company. Mr. Katz is presently a member
of the Board of Directors of the following publicly-held corporations:
Biophan Technologies, Inc., Nanoscience Technologies, Inc., NaturalNano,
Inc., and USA Technologies, Inc.
Mr. Passner has been an independent consultant since 2001. Prior to
that, he was a member of the technical staff of Lucent (AT&T) Bell
Laboratories for over 30 years. Mr. Passner is a member of the Board of
Directors of Nanoscience Technologies, Inc. and USA Technologies, Inc.
About GammaCan International Inc.:
GammaCan is focusing on the commercialization of an innovative
anti-cancer immunotherapy to treat metastatic cancer. GammaCan's
platform is based on IgG, a safe, relatively non-toxic human
plasma-based product, currently used to treat a variety of immune
deficiencies and autoimmune diseases. IgG works by strengthening the
patient's immune system. Many experts currently view immunotherapy as a
future alternative to today's standard chemotherapy. GammaCan is
developing VitiGam, its second generation program. VitiGam is an IgG
derived from the plasma of vitiligo donors and is being developed to
treat malignant melanoma. GammaCan owns, and has applied for US patent
protection covering the use of IgG and vitiligo-derived IgG (VitiGam).
GammaCan International, Inc., owns an 87 % interest in its Israeli
subsidiary, GammaCan Ltd.
About VitiGam:
VitiGam is GammaCan's second generation intravenous IgG-based product
and a first-in-class anti-cancer immunotherapy. GammaCan plans on having
VitiGam to enter phase I/II testing under a US IND in the near future
after it recently held a pre-IND meeting with the FDA. VitiGam is being
designed to target metastatic melanoma patients with Stage III and IV
melanoma. VitiGam is an IgG product that is different from standard
IgGs: It is manufactured from the plasma of donors with vitiligo, a
benign autoimmune skin condition affecting up to 2% of the general
population. GammaCan scientists have shown that this "enriched" vitiligo
IgG (VitiGam) contains potent anti-melanoma activity in both in vitro
and mouse xenograft melanoma models. Thus, GammaCan expects VitiGam to
provide (1) anti-melanoma activity directed specifically against
malignant melanoma cells and (2) non-specific anti-cancer activity - as
is the case with IgG in general
For more information about GammaCan visit www.GammaCan.com
or call the Company's headquarters in Kiryat Ono, Israel at +972 (03)
738-2616 or toll free 1-866-308-0396 (from North America).
Safe Harbor Statement:
Statements in this document that are not purely historical are
forward-looking statements. Forward-looking statements in this release
include statements regarding the commercialization of an anti-cancer
immunotherapy and the Company developing the boosting of cancer
patients' immune systems with IgG into an effective treatment. Actual
outcomes and the Company's actual results could differ materially from
those in such forward-looking statements. Factors that could cause
actual results to differ materially include risks and uncertainties such
as the inability to finance the planned development of the technology,
unforeseen technical difficulties in developing the technology, the
inability to obtain regulatory approval for human use, competitors'
therapies proving more effective, cheaper or otherwise preferable for
consumers, inability to market the product we produce, among other
factors, all of which could among other things, delay or prevent product
release or cause our company to fail. For further risk factors see the
risk factors associated with other early state medical research and
development companies filed with the SEC on Edgar.
GammaCan International, Inc. (OTC BB: GCAN), a developer of
immunotherapies for the treatment of melanoma and other cancers, today
announced the reorganization of its Board of Directors.
Mr. Steven Katz and Mr. Albert Passner have joined the Board of
Directors of GammaCan International Inc. Mr. Katz has also been named
Chairman of the Board. At the same time, Dr. Lior Soussan-Gutman and
Mr. Jean-Pierre Elisha Martinez have left the Board of GammaCan
International Inc. and continue as Directors of GammaCan Ltd., a
subsidiary.
"We are pleased to have Steven and Albert join our Board. Steven
brings extensive industry experience to GammaCan. He is a successful
entrepreneur, management consultant and life sciences executive.
GammaCan will be able to utilize Steven's industry background and
experience as well as take advantage of both Steven's and Al's
experience as Directors of public companies", commented Patrick
Schnegelsberg, GammaCan's CEO.
Mr. Katz is currently the President of Steven Katz & Associates,
Inc., a health care and technology based management consulting firm
specializing in strategic planning, corporate development, new product
planning, technology licensing and structuring and securing various
forms of financing. Mr. Katz also served as President, Chief Operating
Officer and Director of Senesco Technologies, Inc., an American Stock
Exchange listed company, engaged in the identification and development
of proprietary gene technology with application to human, animal and
plant systems. He co-founded and served as Executive Vice President of
S.K.Y. Polymers, Inc., a bio-materials company. Mr. Katz is presently
a member of the Board of Directors of the following publicly-held
corporations: Biophan Technologies, Inc., Nanoscience Technologies,
Inc., NaturalNano, Inc., and USA Technologies, Inc.
Mr. Passner has been an independent consultant since 2001. Prior
to that, he was a member of the technical staff of Lucent (AT&T) Bell
Laboratories for over 30 years. Mr. Passner is a member of the Board
of Directors of Nanoscience Technologies, Inc. and USA Technologies,
Inc.
About GammaCan International Inc.:
GammaCan is focusing on the commercialization of an innovative
anti-cancer immunotherapy to treat metastatic cancer. GammaCan's
platform is based on IgG, a safe, relatively non-toxic human
plasma-based product, currently used to treat a variety of immune
deficiencies and autoimmune diseases. IgG works by strengthening the
patient's immune system. Many experts currently view immunotherapy as
a future alternative to today's standard chemotherapy. GammaCan is
developing VitiGam, its second generation program. VitiGam is an IgG
derived from the plasma of vitiligo donors and is being developed to
treat malignant melanoma. GammaCan owns, and has applied for US patent
protection covering the use of IgG and vitiligo-derived IgG (VitiGam).
GammaCan International, Inc., owns an 87 % interest in its Israeli
subsidiary, GammaCan Ltd.
About VitiGam:
VitiGam is GammaCan's second generation intravenous IgG-based
product and a first-in-class anti-cancer immunotherapy. GammaCan plans
on having VitiGam to enter phase I/II testing under a US IND in the
near future after it recently held a pre-IND meeting with the FDA.
VitiGam is being designed to target metastatic melanoma patients with
Stage III and IV melanoma. VitiGam is an IgG product that is different
from standard IgGs: It is manufactured from the plasma of donors with
vitiligo, a benign autoimmune skin condition affecting up to 2% of the
general population. GammaCan scientists have shown that this
"enriched" vitiligo IgG (VitiGam) contains potent anti-melanoma
activity in both in vitro and mouse xenograft melanoma models. Thus,
GammaCan expects VitiGam to provide (1) anti-melanoma activity
directed specifically against malignant melanoma cells and (2)
non-specific anti-cancer activity - as is the case with IgG in general
For more information about GammaCan visit www.GammaCan.com or call
the Company's headquarters in Kiryat Ono, Israel at +972 (03) 738-2616
or toll free 1-866-308-0396 (from North America).
Safe Harbor Statement:
Statements in this document that are not purely historical are
forward-looking statements. Forward-looking statements in this release
include statements regarding the commercialization of an anti-cancer
immunotherapy and the Company developing the boosting of cancer
patients' immune systems with IgG into an effective treatment. Actual
outcomes and the Company's actual results could differ materially from
those in such forward-looking statements. Factors that could cause
actual results to differ materially include risks and uncertainties
such as the inability to finance the planned development of the
technology, unforeseen technical difficulties in developing the
technology, the inability to obtain regulatory approval for human use,
competitors' therapies proving more effective, cheaper or otherwise
preferable for consumers, inability to market the product we produce,
among other factors, all of which could among other things, delay or
prevent product release or cause our company to fail. For further risk
factors see the risk factors associated with other early state medical
research and development companies filed with the SEC on Edgar.